Skip to main content

Advertisement

SpringerLink
Log in

Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Medullary thyroid carcinoma (MTC) originates from thyroid parafollicular C-cells and represents <5% of all thyroid cancers. Serum Calcitonin (CTn) is considered the most sensitive marker of persistent or recurrent disease and is measured in association to CEA. According to the American Thyroid Association (ATA) guidelines, following initial surgery when CTn level remains below 150 pg/mL, follow-up may rely on repeated serum marker determinations and on neck ultrasonography (US). When CTn level exceeds 150 pg/ml, additional imaging is required. In this review, we provide an overview of available imaging tools to monitor MTC course and propose an effective imaging strategy for MTC patients according to their clinical situation.

Methods

A literature search focusing on available imaging tools to monitor MTC provided the currently available information for this review. Recent evidence-based reports and reviews were considered as priority over older evidence.

Results

For MTC patients with detectable CTn levels and disease recurrence, PET/CT imaging with 18F-DOPA or 68Ga-DOTA-peptides present the best sensitivity for lesion detection. 18F FDG PET/CT represents a prognostic tool and is useful in case of aggressive disease. Neck ultrasound, chest CT scan and MRI of the liver and of the axial skeleton represent complementary techniques. Beyond the diagnostic accuracy, the clinical impact of imaging is variable according to different disease settings and tumor marker levels. Finally, other applications of imaging such as response to focal and systemic treatments and new promising PET tracers should be further investigated.

Conclusion

The role of imaging in MTC patients improved, especially with the use of 18F-DOPA PET/CT that provides high quality diagnostic images. However, the impact on therapeutic management should be further evaluated in the different disease settings and in proper prospective trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. S.A. Wells Jr, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel et al. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  2. J. Barbet, L. Campion, F. Kraeber-Bodere, J.F. Chatal; Group GTES, Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 90, 6077–6084 (2005)

    Article  CAS  PubMed  Google Scholar 

  3. A.L. Giraudet, A. Al Ghulzan, A. Aupérin, S. Leboulleux, A. Chehboun, F. Troalen et al. Progression of medullary thyroid carcinoma: assessment with Calcitonin and CEA doubling times. Eur. J. Endocrinol. 158, 239–46 (2008)

    Article  CAS  Google Scholar 

  4. E. Fialkowski, M. De Benedetti, J. Moley, Long-term outcome of reoperations for medullary thyroid carcinoma. World J. Surg. 32, 754–65 (2008)

    Article  PubMed  Google Scholar 

  5. G. Pellegriti, S. Leboulleux, E. Baudin, N. Bellon, C. Scollo, J.P. Travagli et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br. J. Cancer 88, 1537–42 (2003)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. J.A. van Heerden, C.S. Grant, H. Gharib, I.D. Hay, D.M. Ilstrup, Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann. Surg. 212, 395–400 (1990)

    Article  PubMed  PubMed Central  Google Scholar 

  7. S. Asa, K. Sonmezoglu, L. Uslu-Besli, O.E. Sahin, E. Karayel, H. Pehlivanoglu et al. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. Ann. Nucl. Med. 35, 900–915 (2021)

    Article  CAS  PubMed  Google Scholar 

  8. L. Giovanella, G. Treglia, I. Iakovou, J. Mihailovic, F.A. Verburg, M. Luster., EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 47, 61–77 (2020)

    Article  PubMed  Google Scholar 

  9. F. Castinetti, D. Taïeb, Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal? Thyroid 31, 151–155 (2021)

    Article  PubMed  Google Scholar 

  10. G. Treglia, C. Aktolun, A. Chiti, S. Frangos, L. Giovanella, M. Hoffmann et al. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine. Eur. J. Nucl. Med. Mol. Imaging 43, 1486–1490 (2016)

    Article  PubMed  Google Scholar 

  11. J. Leclere, S. Sidibé, N. Lassau et al. Ultrasonographic aspects of hepatic metastases of thyroid medullary cancers. Eur. J. Radiol. 77, 99–103 (1996)

    CAS  Google Scholar 

  12. S.V. Kushchayev, Y.S. Kushchayeva, S.H. Tella, T. Glushko, K. Pacak, O.M. Teytelboym, Medullary Thyroid Carcinoma: An Update on Imaging. J. Thyroid Res. 2019, 1893047 (2019)

    Article  PubMed  PubMed Central  Google Scholar 

  13. C. Dromain, T. de Baère, E. Baudin, J. Galline, M. Ducreux, V. Boige et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. Am. J. Roentgenol. 180, 121–8 (2003)

    Article  Google Scholar 

  14. M. Terroir, C. Caramella, I. Borget, S. Bidault, C. Dromain, K. El Farsaoui et al. F-18-dopa positron emission tomography/computed tomography is more sensitive than whole-body magnetic resonance imaging for the localization of persistent/recurrent disease of medullary thyroid cancer patients. Thyroid 29, 1457–64 (2019)

    Article  CAS  PubMed  Google Scholar 

  15. G. Treglia, L. Giovanella, 18F-Fluoride (18F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines! Eur. J. Nucl. Med. Mol. Imaging 47, 527–8 (2020)

    Article  PubMed  Google Scholar 

  16. C.E. Ueda, P.S. Duarte, L.A. de Castroneves, G.B. Coura-Filho, H.N. Sado, M.T. Sapienza et al. Comparison of (18)F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases. Nucl. Med. Mol. Imaging 54, 281–91 (2020)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. E. Baudin, J. Lumbroso, M. Schlumberger, J. Leclere, F. Giammarile, P. Gardet et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J. Nucl. Med. 37, 912–6 (1996)

    CAS  PubMed  Google Scholar 

  18. S.E. Clarke, C.R. Lazarus, P. Wraight, C. Sampson, M.N. Maisey, Pentavalent [99mTc] DMSA, [131I] MIBG, and [99mTc]MDP–an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J. Nucl. Med. 29, 33–8 (1988)

    CAS  PubMed  Google Scholar 

  19. I. Ilias, C. Divgi, K. Pacak, Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin. Nucl. Med. 41, 364–8 (2011)

    Article  PubMed  PubMed Central  Google Scholar 

  20. U. Verga, F. Muratori, G. Di Sacco, F. Banfi, A. Libroia, The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma. Henry Ford. Hosp. Med. J. 37, 175–7 (1989)

    CAS  PubMed  Google Scholar 

  21. A.L. Giraudet, D. Vanel, S. Leboulleux, A. Aupérin, C. Dromain, L. Chami et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185–90 (2007)

    Article  CAS  PubMed  Google Scholar 

  22. S.C. Ong, H. Schöder, S.G. Patel, I.M. Tabangay-Lim, I. Doddamane, M. Gönen et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J. Nucl. Med. 48, 501–7 (2007)

    Article  CAS  PubMed  Google Scholar 

  23. G. Treglia, M.F. Villani, A. Giordano, V. Rufini, Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42, 535–45 (2012)

    Article  CAS  PubMed  Google Scholar 

  24. A. Archier, C. Heimburger, C. Guerin, I. Morange, F.F. Palazzo, J.F. Henry et al. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 43, 1027–33 (2016)

    Article  CAS  PubMed  Google Scholar 

  25. M. Beheshti, S. Pocher, R. Vali, P. Waldenberger, G. Broinger, M. Nader et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur. Radio. 19, 1425–34 (2009)

    Article  Google Scholar 

  26. B. Beuthien-Baumann, A. Strumpf, J. Zessin, J. Bredow, J. Kotzerke, Diagnostic impact of PET with 18 F-FDG, 18 F-DOPA and 3-O-methyl-6- [18 F] fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 34, 1604–9 (2007)

    Article  CAS  PubMed  Google Scholar 

  27. G. Glatting, A.K. Buck, C. Solbach, B. Neumaier, S.N. Reske, F.M. Mottaghy, Clinical value of 18- fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20, 527–33 (2010)

    Article  PubMed  Google Scholar 

  28. S. Hoegerle, C. Altehoefer, N. Ghanem, I. Brink, E. Moser, E. Nitzsche, 18 F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med. 28, 64–71 (2001)

    Article  CAS  PubMed  Google Scholar 

  29. S. Kauhanen, C. Schalin-Jantti, M. Seppanen, S. Kajander, S. Virtanen, J. Schildt et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J. Nucl. Med. 52, 1855–63 (2011)

    Article  CAS  PubMed  Google Scholar 

  30. K.P. Koopmans, L.W.B. de Groot, J.T. Plukker, E.G. de Vries, I.P. Kema, W.J. Sluiter et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J. Nucl. Med. 49, 524–31 (2008)

    Article  CAS  PubMed  Google Scholar 

  31. M. Luster, W. Karges, K. Zeich, S. Pauls, F.A. Verburg, H. Dralle et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20, 527–33 (2010)

    Article  CAS  PubMed  Google Scholar 

  32. M. Marzola, M. Pelizzo, M. Ferdeghini, A. Toniato, A. Massaro, V. Ambrosini et al. Dual PET/CT with 18F-DOPA and 18F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur. J. Surg. Oncol. (EJSO) 36, 414–21 (2010)

    Article  CAS  Google Scholar 

  33. A.R. Romero-Lluch, J.I. Cuenca-Cuenca, R. Guerrero-Vázquez, A.J. Martínez-Ortega, I. Borrego-Dorado, E. Navarro-González, Diagnostic utility of PET/CT with 18 F-DOPA and 18 F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur. J. Nucl. Med. Mol. Imaging 44, 2004–13. (2017)

    Article  CAS  PubMed  Google Scholar 

  34. M. Soussan, V. Nataf, K. Kerrou, D. Grahek, O. Pascal, J.N. Talbot et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl. Med. Commun. 33, 775–9 (2012)

    Article  PubMed  Google Scholar 

  35. T. Traub-Weidinger, D. Putzer, E. von Guggenberg, G. Dobrozemsky, B. Nilica, D. Kendler et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur. J. Nucl. Med. Mol. Imaging 42, 1995–2001 (2015)

    Article  CAS  PubMed  Google Scholar 

  36. G. Treglia, P. Castaldi, M.F. Villani, G. Perotti, C. de Waure, A. Filice et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569–80 (2012)

    Article  CAS  PubMed  Google Scholar 

  37. G. Treglia, A. Stefanelli, P. Castaldi, V. Rufini, A standardized dual-phase 18F-DOPA PET/CT protocol in the detection of medullary thyroid cancer. Nucl. Med. Commun. 34, 185–6 (2013)

    Article  PubMed  Google Scholar 

  38. H.H. Verbeek, J.T. Plukker, K.P. Koopmans, J.W. de Groot, R.M. Hofstra, A.C. Muller Kobold et al. Clinical relevance of 18F- FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J. Nucl. Med. 53, 1863–71 (2012)

    Article  CAS  PubMed  Google Scholar 

  39. D.J. Kwekkeboom, J.C. Reubi, S.W. Lamberts, H.A. Bruining, A.H. Mulder, H.Y. Oei, E.P. Krenning, In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 76, 1413–7 (1993)

    CAS  PubMed  Google Scholar 

  40. D. Puhr-Westerheide, C.C. Cyran, J. Sargsyan-Bergmann, A. Todica, F.J. Gildehaus, W.G. Kunz et al. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18 F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma. Cancer Imaging 19, 73 (2019)

    Article  PubMed  PubMed Central  Google Scholar 

  41. L.A. Castroneves, G. Coura Filho, R.M.C. de Freitas, R. Salles, R.A. Moyses, R.V.M. Lopez et al. Comparison of 68Ga PET/CT to other imaging studies in medullary thyroid cancer: superiority in detecting bone metastases. J. Clin. Endocrinol. Metab. 103, 3250–9 (2018)

    Article  PubMed  Google Scholar 

  42. B.G. Conry, N.D. Papathanasiou, V. Prakash et al. Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 37, 49–57 (2010)

    Article  CAS  PubMed  Google Scholar 

  43. E.C.S. de Camargo Etchebehere, S.A. de Oliveira, B. Gumz, A. Vicente, P.G. Hoff, G. Corradi et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J. Nucl. Med. 55, 1598–604 (2014)

    Article  Google Scholar 

  44. D. Putzer, A. Kroiss, D. Waitz, M. Gabriel, T. Traub-Weidinger, C. Uprimny et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur. J. Nucl. Med. Mol. Imaging 40, 364–72 (2013)

    Article  CAS  PubMed  Google Scholar 

  45. P. Souteiro, P. Gouveia, G. Ferreira, S. Belo, C. Costa, D. Carvalho et al. 68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers. Endocrine 64, 322–9 (2019)

    Article  CAS  PubMed  Google Scholar 

  46. L.Y.I. Yamaga, M.L. Cunha, G.C. Campos Neto, M.R.T. Garcia, J.H. Yang, C.P. Camacho, et al. 68) Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111) In-octreotide SPECT/CT and conventional imaging. Eur. J. Nucl. Med. Mol. Imaging 44, 1695–701 (2017).

    Article  CAS  PubMed  Google Scholar 

  47. S.W. Lee, S.R. Shim, S.Y. Jeong, S.J. Kim, Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis. Clin. Nucl. Med. 45, 341–8 (2020)

    Article  PubMed  Google Scholar 

  48. C. Bodet-Milin, A. Faivre-Chauvet, T. Carlier, C. Ansquer, A. Rauscher, E. Frampas et al. Anti-CEA pretargeted Immuno-PET shows higher sensitivity than DOPA-PET/CT to detect relapsing metastatic medullary thyroid carcinoma: Post- hoc analysis of the iPET-MTC study. J. Nucl. Med. 62, 1221–7 (2021)

    Article  CAS  PubMed  Google Scholar 

  49. L.J. Wirth, E. Sherman, B. Robinson, B. Solomon, H. Kang, J. Lorch et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N. Engl. J. Med. 383, 825–35 (2020)

    Article  CAS  PubMed  Google Scholar 

  50. D. Salvatore, M. Santoro, M. Schlumberger, The importance of the RET gene in thyroid cancer and therapeutic implications. Nat. Rev. Endocrinol. 17, 296–306 (2021)

    Article  CAS  PubMed  Google Scholar 

  51. A. Kaloudi, B.A. Nock, E.P. Krenning, T. Maina, M. De Jong, M. Radiolabeled, gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting. Q J. Nucl. Med. Mol. Imaging 59, 287–302 (2015)

    CAS  PubMed  Google Scholar 

  52. C. Uprimny, E. von Guggenberg, A. Svirydenka, R. Mikołajczak, A. Hubalewska-Dydejczyk, I.J. Virgolini, Comparison of PET/CT imaging with [(18)F] FDOPA and cholecystokinin-2 receptor targeting [(68) Ga] Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 48, 935–6 (2021)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Advanced Biomedical Sciences, University of Naples “Federico II”, Naples, Italy

    Michele Klain, Carmela Nappi & Alberto Cuocolo

  2. Department of Endocrine Oncology and Nuclear Medicine, Gustave Roussy and University Paris-Saclay, Villejuif, France

    Julien Hadoux & Martin Schlumberger

  3. Department of Medical Science, Nuclear Medicine Division, University of Turin, Turin, Italy

    Monica Finessi & Désirée Deandreis

  4. IRCCS SDN, Naples, Italy

    Raffaele Ambrosio

  5. Department of Public Health, University of Naples “Federico II”, Naples, Italy

    Domenico Salvatore

Authors
  1. Michele Klain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julien Hadoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carmela Nappi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Monica Finessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raffaele Ambrosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin Schlumberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alberto Cuocolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Désirée Deandreis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Domenico Salvatore
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to conceptualizing this review. M.K. wrote the first draft. All authors edited and revised the paper and approved the final version.

Funding

This work was supported by the Ministero dell’Istruzione dell’Università e della Ricerca (PRIN 2017, protocol 2017YTWKWH) to D.S.

Corresponding author

Correspondence to Domenico Salvatore.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethical approval

This paper does not contain any unpublished studies with animals or human participants performed by any of the authors.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klain, M., Hadoux, J., Nappi, C. et al. Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives. Endocrine 75, 330–337 (2022). https://doi.org/10.1007/s12020-021-02930-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-021-02930-8

Keywords

Search

Navigation